{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T21:07:25Z","timestamp":1774818445633,"version":"3.50.1"},"reference-count":267,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ccm.2023.08.010","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T06:27:12Z","timestamp":1694240832000},"page":"131-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anti-inflammatory Therapy for Sarcoidosis"],"prefix":"10.1016","volume":"45","author":[{"given":"Ogugua Ndili","family":"Obi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ccm.2023.08.010_bib1","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","article-title":"Diagnosis and detection of sarcoidosis. An Official American Thoracic society clinical practice guideline","volume":"201","author":"Crouser","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib2","first-page":"149","article-title":"ATS\/ERS\/WASOG statement on sarcoidosis. American Thoracic society\/European respiratory society\/world association of sarcoidosis and other granulomatous Disorders","volume":"16","author":"Hunninghake","year":"1999","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"10 Pt 1","key":"10.1016\/j.ccm.2023.08.010_bib3","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1164\/ajrccm.164.10.2104046","article-title":"Clinical characteristics of patients in a case control study of sarcoidosis","volume":"164","author":"Baughman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2023.08.010_bib4","doi-asserted-by":"crossref","first-page":"106564","DOI":"10.1016\/j.rmed.2021.106564","article-title":"The impact of demographic disparities in the presentation of sarcoidosis: a multicenter prospective study","volume":"187","author":"Zhou","year":"2021","journal-title":"Respir Med"},{"key":"10.1016\/j.ccm.2023.08.010_bib5","article-title":"Systemic treatment in sarcoidosis: experience over two decades","author":"Fernandez-Ramon","year":"2022","journal-title":"Eur J Intern Med"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.010_bib6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"issue":"155","key":"10.1016\/j.ccm.2023.08.010_bib7","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0146-2019","article-title":"Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis","volume":"29","author":"Rahaghi","year":"2020","journal-title":"Eur Respir Rev"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.010_bib8","first-page":"204","article-title":"Two year prognosis of sarcoidosis: the ACCESS experience","volume":"20","author":"Judson","year":"2003","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-019-0096-x","article-title":"Sarcoidosis","volume":"5","author":"Grunewald","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"10.1016\/j.ccm.2023.08.010_bib10","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra2101555","article-title":"Challenges of sarcoidosis and its management","volume":"385","author":"Drent","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib11","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/MCP.0000000000000612","article-title":"Advanced sarcoidosis","volume":"25","author":"Baughman","year":"2019","journal-title":"Curr Opin Pulm Med"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1183\/09031936.00002512","article-title":"Sarcoidosis-associated fatigue","volume":"40","author":"Drent","year":"2012","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/1479972316661926","article-title":"Managing fatigue in sarcoidosis - a systematic review of the evidence","volume":"14","author":"Atkins","year":"2017","journal-title":"Chron Respir Dis"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.010_bib14","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3390\/pathophysiology28040035","article-title":"Small fiber neuropathy in sarcoidosis","volume":"28","author":"Gavrilova","year":"2021","journal-title":"Pathophysiology"},{"key":"10.1016\/j.ccm.2023.08.010_bib15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.rmed.2017.03.011","article-title":"Sarcoidosis-associated small fiber neuropathy in a large cohort: clinical aspects and response to IVIG and anti-TNF alpha treatment","volume":"126","author":"Tavee","year":"2017","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib16","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/MCP.0000000000000893","article-title":"Novel insights in fibrotic pulmonary sarcoidosis","volume":"28","author":"Comes","year":"2022","journal-title":"Curr Opin Pulm Med"},{"issue":"166","key":"10.1016\/j.ccm.2023.08.010_bib17","first-page":"31","article-title":"Immune mechanisms in fibrotic pulmonary sarcoidosis","author":"Weeratunga","year":"2022","journal-title":"Eur Respir Rev"},{"issue":"10","key":"10.1016\/j.ccm.2023.08.010_bib18","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S2213-2600(15)00199-X","article-title":"New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches","volume":"3","author":"Baughman","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"6 Pt 1","key":"10.1016\/j.ccm.2023.08.010_bib19","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1164\/ajrccm\/142.6_Pt_1.1268","article-title":"The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis","volume":"142","author":"Baughman","year":"1990","journal-title":"Am Rev Respir Dis"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.010_bib20","doi-asserted-by":"crossref","first-page":"755","DOI":"10.4049\/jimmunol.139.3.755","article-title":"Corticosteroid therapy suppresses spontaneous interleukin 2 release and spontaneous proliferation of lung T lymphocytes of patients with active pulmonary sarcoidosis","volume":"139","author":"Pinkston","year":"1987","journal-title":"J\u00a0Immunol"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cardfail.2021.07.008","article-title":"Rituximab for the treatment of refractory cardiac sarcoidosis: a single-center experience","volume":"28","author":"Elwazir","year":"2022","journal-title":"J\u00a0Card Fail"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib22","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1183\/09031936.00224513","article-title":"Rituximab in the treatment of refractory pulmonary sarcoidosis","volume":"43","author":"Sweiss","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2023.08.010_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418805732","article-title":"Successful therapy with rituximab in three patients with probable neurosarcoidosis","volume":"11","author":"Zella","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.010_bib24","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/09273948.2012.762982","article-title":"Successful treatment of ocular sarcoidosis with rituximab","volume":"21","author":"Beccastrini","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ccm.2023.08.010_bib25","first-page":"1613","article-title":"Rituximab for refractory granulomatous eye disease","volume":"6","author":"Lower","year":"2012","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.010_bib26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00408-017-9994-4","article-title":"Repository corticotropin for chronic pulmonary sarcoidosis","volume":"195","author":"Baughman","year":"2017","journal-title":"Lung"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.010_bib27","first-page":"192","article-title":"Repository corticotropin injection (H.P. Acthar gel) for the treatment of sarcoidosis-induced hypercalciuria and vitamin D dysregulation: a pilot, open label study","volume":"35","author":"Judson","year":"2018","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.ccm.2023.08.010_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/1753466619888127","article-title":"Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records","volume":"13","author":"Chopra","year":"2019","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.ccm.2023.08.010_bib29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejim.2021.12.016","article-title":"Glucocorticoid sparing in sarcoidosis using the Janus kinase (JAK) inhibitor tofacitinib","volume":"98","year":"2022","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib30","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1038\/s41467-022-30615-x","article-title":"Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis","volume":"13","author":"Damsky","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ccm.2023.08.010_bib31","article-title":"Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare","author":"Damsky","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00408-021-00436-8","article-title":"Tofacitinib as a steroid-sparing therapy in pulmonary sarcoidosis, an open-label prospective proof-of-concept study","volume":"199","author":"Friedman","year":"2021","journal-title":"Lung"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib33","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaad.2020.10.016","article-title":"Tofacitinib for cutaneous and pulmonary sarcoidosis: a case series","volume":"84","author":"Kerkemeyer","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.ccm.2023.08.010_bib34","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/1756-185X.14441","article-title":"Tofacitinib for sarcoidosis, a new potential treatment","volume":"25","author":"Xu","year":"2022","journal-title":"Int J Rheum Dis"},{"issue":"26","key":"10.1016\/j.ccm.2023.08.010_bib35","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis","volume":"379","author":"Damsky","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib36","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/acr2.11112","article-title":"Treatment of Multiorgan sarcoidosis with tofacitinib","volume":"2","author":"Damsky","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.ccm.2023.08.010_bib37","doi-asserted-by":"crossref","first-page":"991783","DOI":"10.3389\/fmed.2022.991783","article-title":"Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches","volume":"9","author":"Obi","year":"2022","journal-title":"Front Med"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib38","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/qjmed\/hcl038","article-title":"Presenting characteristics as predictors of duration of treatment in sarcoidosis","volume":"99","author":"Baughman","year":"2006","journal-title":"QJM"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib39","first-page":"119","article-title":"The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States","volume":"29","author":"Judson","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib40","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.chest.2017.07.008","article-title":"Predictors of mortality in pulmonary sarcoidosis","volume":"153","author":"Kirkil","year":"2018","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.ccm.2023.08.010_bib41","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1164\/rccm.201010-1679OC","article-title":"Sarcoidosis-related mortality in the United States from 1988 to 2007","volume":"183","author":"Swigris","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib42","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01747-2019","article-title":"Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry","volume":"55","author":"Shlobin","year":"2020","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-2600(13)70276-5","article-title":"An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study","volume":"2","author":"Walsh","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ccm.2023.08.010_bib44","doi-asserted-by":"crossref","first-page":"105997","DOI":"10.1016\/j.rmed.2020.105997","article-title":"Predictors of mortality in fibrosing pulmonary sarcoidosis","volume":"169","author":"Jeny","year":"2020","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib45","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1055\/s-0040-1709495","article-title":"Advanced pulmonary sarcoidosis","volume":"41","author":"Gupta","year":"2020","journal-title":"Semin Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib46","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.nephro.2021.08.001","article-title":"[Renal involvement in sarcoidosis: Prognostic and predictive factors]","volume":"18","author":"Gorsane","year":"2022","journal-title":"Nephrol Ther"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib47","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00408-019-00206-7","article-title":"The burden of sarcoidosis symptoms from a patient Perspective","volume":"197","author":"Voortman","year":"2019","journal-title":"Lung"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.010_bib48","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1378\/chest.130.4.989","article-title":"Fatigue is associated with quality of life in sarcoidosis patients","volume":"130","author":"Michielsen","year":"2006","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib49","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/MCP.0000000000000597","article-title":"Nonorgan manifestations of sarcoidosis","volume":"25","author":"Tavee","year":"2019","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.ccm.2023.08.010_bib50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4137\/IMI.S12783","article-title":"Shared decision making: a fundamental tenet in a conceptual framework of integrative healthcare delivery","volume":"8","author":"Brooks","year":"2013","journal-title":"Integr Med Insights"},{"key":"10.1016\/j.ccm.2023.08.010_bib51","first-page":"109","article-title":"Fostering shared decision making with health Informatics interventions based on the Boosting framework","volume":"263","author":"de Vries","year":"2019","journal-title":"Stud Health Technol Inform"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.010_bib52","doi-asserted-by":"crossref","first-page":"101695","DOI":"10.1016\/j.berh.2021.101695","article-title":"Exercise as a multi-modal disease-modifying medicine in systemic sclerosis: an introduction by the global Fellowship on Rehabilitation and exercise in systemic sclerosis (G-FoRSS)","volume":"35","author":"Pettersson","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib53","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/BOR.0b013e32834f19f5","article-title":"Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies","volume":"24","author":"Alexanderson","year":"2012","journal-title":"Curr Opin Rheumatol"},{"issue":"10","key":"10.1016\/j.ccm.2023.08.010_bib54","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/17476348.2016.1227244","article-title":"Physical activity and training in sarcoidosis: review and experience-based recommendations","volume":"10","author":"Strookappe","year":"2016","journal-title":"Expert Rev Respir Med"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.010_bib55","doi-asserted-by":"crossref","first-page":"101707","DOI":"10.1016\/j.berh.2021.101707","article-title":"A\u00a0comprehensive framework for navigating patient care in systemic sclerosis: a global response to the need for improving the practice of diagnostic and preventive strategies in SSc","volume":"35","author":"Saketkoo","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib56","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00408-015-9784-9","article-title":"Benefits of physical training in sarcoidosis","volume":"193","author":"Strookappe","year":"2015","journal-title":"Lung"},{"issue":"Supplement_6","key":"10.1016\/j.ccm.2023.08.010_bib57","doi-asserted-by":"crossref","first-page":"S429","DOI":"10.1513\/AnnalsATS.201707-565OT","article-title":"Genetic, Immunologic, and Environmental Basis of sarcoidosis","volume":"14","author":"Moller","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.ccm.2023.08.010_bib58","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3389\/fimmu.2013.00437","article-title":"Granuloma formation in pulmonary sarcoidosis","volume":"4","author":"Broos","year":"2013","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.010_bib59","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ccm.2008.03.014","article-title":"The immunology of sarcoidosis","volume":"29","author":"Gerke","year":"2008","journal-title":"Clin Chest Med"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib60","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/thx.2010.140319","article-title":"Sarcoidosis is a Th1\/Th17 multisystem disorder","volume":"66","author":"Facco","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2023.08.010_bib61","doi-asserted-by":"crossref","first-page":"106161","DOI":"10.1016\/j.rmed.2020.106161","article-title":"Current perspectives on the immunopathogenesis of sarcoidosis","volume":"173","author":"Lee","year":"2020","journal-title":"Respir Med"},{"issue":"12","key":"10.1016\/j.ccm.2023.08.010_bib62","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.4049\/jimmunol.156.12.4952","article-title":"Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis","volume":"156","author":"Moller","year":"1996","journal-title":"J\u00a0Immunol"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib63","doi-asserted-by":"crossref","first-page":"642","DOI":"10.4049\/jimmunol.166.1.642","article-title":"IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs","volume":"166","author":"Shigehara","year":"2001","journal-title":"J\u00a0Immunol"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib64","first-page":"120","article-title":"Th1 and Th2 responses regulate experimental lung granuloma development","volume":"13","author":"Kunkel","year":"1996","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib65","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1084\/jem.20050648","article-title":"The immune paradox of sarcoidosis and regulatory T cells","volume":"203","author":"Miyara","year":"2006","journal-title":"J\u00a0Exp Med"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib66","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.clim.2011.03.015","article-title":"Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation","volume":"140","author":"Rappl","year":"2011","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ccm.2023.08.010_bib67","article-title":"Phagosome-regulated mTOR Signalling during sarcoidosis granuloma Biogenesis","author":"Crouser","year":"2020","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib68","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1038\/s41598-017-04109-6","article-title":"Identification of Jak-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib69","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2353\/ajpath.2009.080580","article-title":"FoxP3+ regulatory T cells suppress early stages of granuloma formation but have little impact on sarcoidosis lesions","volume":"174","author":"Taflin","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ccm.2023.08.010_bib70","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jaut.2017.12.012","article-title":"Th17-lineage cells in pulmonary sarcoidosis and L\u00f6fgren's syndrome: Friend or foe?","volume":"87","author":"Miedema","year":"2018","journal-title":"J\u00a0Autoimmun"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.010_bib71","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01124-2017","article-title":"Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes","volume":"51","author":"Broos","year":"2018","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib72","first-page":"e2023011","article-title":"Efzofitimod: a novel anti-inflammatory agent for sarcoidosis","volume":"40","author":"Baughman","year":"2023","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.ccm.2023.08.010_bib73","first-page":"1","article-title":"Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update","volume":"31","author":"Obi","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.ccm.2023.08.010_bib74","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/BF02142475","article-title":"[Therapeutic experiences with dexamethasone in pulmonary sarcoidosis (Boeck's disease)]","volume":"123","author":"Wurm","year":"1960","journal-title":"Beitr Klin Tuberk Spezif Tuberkuloseforsch"},{"key":"10.1016\/j.ccm.2023.08.010_bib75","doi-asserted-by":"crossref","first-page":"105936","DOI":"10.1016\/j.rmed.2020.105936","article-title":"Randomised, placebo-controlled trial of dexamethasone for quality of life in pulmonary sarcoidosis","volume":"165","author":"Vis","year":"2020","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.010_bib76","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1001\/jama.1953.03690040012005","article-title":"Local injection of hydrocortisone and cortisone into skin lesions of sarcoidosis","volume":"152","author":"Sullivan","year":"1953","journal-title":"J\u00a0Am Med Assoc"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.010_bib77","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/thx.51.3.238","article-title":"British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment","volume":"51","author":"Gibson","year":"1996","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib78","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1378\/chest.121.1.24","article-title":"Early treatment of stage II sarcoidosis improves 5-year pulmonary function","volume":"121","author":"Pietinalho","year":"2002","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.010_bib79","first-page":"215","article-title":"Corticosteroid therapy of pulmonary sarcoidosis. A prospective evaluation of alternate day and daily dosage in stage II disease","volume":"60","author":"Selroos","year":"1979","journal-title":"Scand J Respir Dis"},{"issue":"9","key":"10.1016\/j.ccm.2023.08.010_bib80","first-page":"496","article-title":"Corticosteroid therapy in sarcoidosis. A five-year, controlled follow-up study","volume":"87","author":"Zaki","year":"1987","journal-title":"N\u00a0Y State J Med"},{"issue":"7515","key":"10.1016\/j.ccm.2023.08.010_bib81","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0140-6736(67)90493-X","article-title":"Treatment of sarcoidosis. Report of a controlled therapeutic trial","volume":"2","author":"James","year":"1967","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.010_bib82","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1164\/arrd.1973.107.4.609","article-title":"A\u00a0controlled trial of prednisone treatment of sarcoidosis","volume":"107","author":"Israel","year":"1973","journal-title":"Am Rev Respir Dis"},{"issue":"9","key":"10.1016\/j.ccm.2023.08.010_bib83","first-page":"1034","article-title":"Corticosteroid therapy for cardiac sarcoidosis: a systematic review","volume":"29","author":"Sadek","year":"2013","journal-title":"Can J Cardiol"},{"issue":"17","key":"10.1016\/j.ccm.2023.08.010_bib84","doi-asserted-by":"crossref","first-page":"e021183","DOI":"10.1161\/JAHA.121.021183","article-title":"Corticosteroid and immunosuppressant therapy for cardiac sarcoidosis: a systematic review","volume":"10","author":"Fazelpour","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib85","first-page":"320","article-title":"Recovery of atrioventricular block following steroid therapy in patients with cardiac sarcoidosis","volume":"62","author":"Yodogawa","year":"2013","journal-title":"J\u00a0Cardiol"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib86","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.amjcard.2004.08.083","article-title":"Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis","volume":"95","author":"Chiu","year":"2005","journal-title":"Am J Cardiol"},{"issue":"16","key":"10.1016\/j.ccm.2023.08.010_bib87","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1001\/archinte.1997.00440370104011","article-title":"Diagnosis and management of neurological sarcoidosis","volume":"157","author":"Lower","year":"1997","journal-title":"Arch Intern Med"},{"issue":"9","key":"10.1016\/j.ccm.2023.08.010_bib88","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1001\/archneur.1995.00540330053014","article-title":"Therapeutic considerations in patients with refractory neurosarcoidosis","volume":"52","author":"Agbogu","year":"1995","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib89","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1378\/chest.08-1347","article-title":"The treatment of lupus pernio: results of 116 treatment courses in 54 patients","volume":"135","author":"Stagaki","year":"2009","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.010_bib90","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.rmed.2015.01.019","article-title":"The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis","volume":"109","author":"Judson","year":"2015","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib91","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.rdc.2015.08.012","article-title":"Corticosteroids in sarcoidosis","volume":"42","author":"Judson","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.ccm.2023.08.010_bib92","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2017.09.003","article-title":"Toxicity risk from glucocorticoids in sarcoidosis patients","volume":"132","author":"Khan","year":"2017","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib93","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00028-2021","article-title":"Type 2 diabetes risk in sarcoidosis patients untreated and treated with corticosteroids","volume":"7","author":"Entrop","year":"2021","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.ccm.2023.08.010_bib94","article-title":"No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis","author":"Broos","year":"2017","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MAJ.0b013e3181b97635","article-title":"Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations","volume":"339","author":"McKinzie","year":"2010","journal-title":"Am J Med Sci"},{"issue":"9","key":"10.1016\/j.ccm.2023.08.010_bib96","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0002-9149(01)01978-6","article-title":"Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone","volume":"88","author":"Yazaki","year":"2001","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib97","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02089-2017","article-title":"Daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis","volume":"51","author":"Broos","year":"2018","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib98","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/archneur.64.5.691","article-title":"Aggressive therapy for neurosarcoidosis: long-term follow-up of 48 treated patients","volume":"64","author":"Scott","year":"2007","journal-title":"Arch Neurol"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.010_bib99","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001084","article-title":"Neurosarcoidosis: Pathophysiology, diagnosis, and treatment","volume":"8","author":"Bradshaw","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib100","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/MCP.0b013e3283642a7a","article-title":"Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide","volume":"19","author":"Cremers","year":"2013","journal-title":"Curr Opin Pulm Med"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib101","first-page":"60","article-title":"Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial","volume":"17","author":"Baughman","year":"2000","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"8","key":"10.1016\/j.ccm.2023.08.010_bib102","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/archinte.1995.00430080088011","article-title":"Prolonged use of methotrexate for sarcoidosis","volume":"155","author":"Lower","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ccm.2023.08.010_bib103","doi-asserted-by":"crossref","first-page":"545413","DOI":"10.3389\/fimmu.2020.545413","article-title":"Treatment of sarcoidosis: a Multidisciplinary approach","volume":"11","author":"Gerke","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib104","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/art.10712","article-title":"Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68","volume":"48","author":"Montesinos","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ccm.2023.08.010_bib105","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/978-1-4615-2584-4_89","article-title":"The antiinflammatory effects of methotrexate are mediated by adenosine","volume":"370","author":"Cronstein","year":"1994","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib106","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.22643","article-title":"The anti-inflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5'-nucleotidase: findings in a study of ecto-5'-nucleotidase gene-deficient mice","volume":"56","author":"Montesinos","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.ccm.2023.08.010_bib107","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/rheumatology\/keg323","article-title":"Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis","volume":"42","author":"Gerards","year":"2003","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.010_bib108","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00000441-199003000-00002","article-title":"The use of low dose methotrexate in refractory sarcoidosis","volume":"299","author":"Lower","year":"1990","journal-title":"Am J Med Sci"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib109","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/00063198-200209000-00022","article-title":"What is the future of methotrexate in sarcoidosis? A study and review","volume":"8","author":"Vucinic","year":"2002","journal-title":"Curr Opin Pulm Med"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.010_bib110","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1378\/chest.12-1728","article-title":"Methotrexate vs azathioprine in second-line therapy of sarcoidosis","volume":"144","author":"Vorselaars","year":"2013","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.010_bib111","first-page":"217","article-title":"Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: a single center real-world study","volume":"36","author":"Fang","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib112","first-page":"26","article-title":"Management of ocular sarcoidosis","volume":"29","author":"Baughman","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"23","key":"10.1016\/j.ccm.2023.08.010_bib113","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.2169\/internalmedicine.53.3120","article-title":"Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions","volume":"53","author":"Nagai","year":"2014","journal-title":"Intern Med"},{"key":"10.1016\/j.ccm.2023.08.010_bib114","article-title":"Cardiac sarcoidosis: systematic review of literature on corticosteroid and immunosuppressive therapies","author":"Stievenart","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2023.08.010_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.970168","article-title":"Epidemiology, clinical presentation, treatment, and outcome of neurosarcoidosis: a mono-centric retrospective study and literature review","volume":"13","author":"Sambon","year":"2022","journal-title":"Front Neurol"},{"issue":"24","key":"10.1016\/j.ccm.2023.08.010_bib116","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1212\/WNL.0000000000003431","article-title":"Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil","volume":"87","author":"Bitoun","year":"2016","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.ccm.2023.08.010_bib117","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jamaneurol.2017.2492","article-title":"Association of Prognostic factors and immunosuppressive treatment with long-term outcomes in neurosarcoidosis","volume":"74","author":"Joubert","year":"2017","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib118","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12883-016-0741-x","article-title":"Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis","volume":"16","author":"Fritz","year":"2016","journal-title":"BMC Neurol"},{"issue":"7","key":"10.1016\/j.ccm.2023.08.010_bib119","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics11071289","article-title":"Efficacy and tolerability of methotrexate and Methylprednisolone in a comparative Assessment of the Primary and long-term outcomes in patients with pulmonary sarcoidosis","volume":"11","author":"Gavrysyuk","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.ccm.2023.08.010_bib120","doi-asserted-by":"crossref","DOI":"10.1177\/14799731211031935","article-title":"Patient reported side-effects of prednisone and methotrexate in a real-world sarcoidosis population","volume":"18","author":"Kahlmann","year":"2021","journal-title":"Chron Respir Dis"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.010_bib121","first-page":"e2020001","article-title":"Methotrexate in sarcoidosis: hematologic and hepatic toxicity encountered in a large cohort over a six year period","volume":"37","author":"Baughman","year":"2020","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib122","first-page":"87","article-title":"Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis","volume":"16","author":"Lewis","year":"1999","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib123","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1183\/09031936.99.14511179","article-title":"Treatment of chronic sarcoidosis with an azathioprine\/prednisolone regimen","volume":"14","author":"Muller-Quernheim","year":"1999","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib124","first-page":"107","article-title":"Azathioprine treatment of chronic pulmonary sarcoidosis","volume":"2","author":"Pacheco","year":"1985","journal-title":"Sarcoidosis"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib125","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/resp.14001","article-title":"Infection risk in sarcoidosis patients treated with methotrexate compared to azathioprine: a retrospective 'target trial' emulated with Swedish real-world data","volume":"26","author":"Rossides","year":"2021","journal-title":"Respirology"},{"issue":"9","key":"10.1016\/j.ccm.2023.08.010_bib126","doi-asserted-by":"crossref","first-page":"e0238391","DOI":"10.1371\/journal.pone.0238391","article-title":"Cardiac sarcoidosis: a long term follow up study","volume":"15","author":"Cacoub","year":"2020","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.ccm.2023.08.010_bib127","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s10072-018-3491-2","article-title":"Neurosarcoidosis: clinical characteristics, diagnosis, and treatment in eight Chinese patients","volume":"39","author":"Wang","year":"2018","journal-title":"Neurol Sci"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.010_bib128","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000743","article-title":"Neurosarcoidosis: Longitudinal experience in a single-center, academic healthcare system","volume":"7","author":"Lord","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"23","key":"10.1016\/j.ccm.2023.08.010_bib129","first-page":"943","article-title":"Neurosarcoidosis. A report of 5 cases","volume":"67","author":"Elkin","year":"1985","journal-title":"S\u00a0Afr Med J"},{"issue":"14","key":"10.1016\/j.ccm.2023.08.010_bib130","doi-asserted-by":"crossref","first-page":"e1479","DOI":"10.1212\/WNL.0000000000200020","article-title":"Prognostic factors and treatment efficacy in Spinal Cord sarcoidosis: an observational cohort with long-term follow-up","volume":"98","author":"Gavoille","year":"2022","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/j.ccm.2023.08.010_bib131","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.jacc.2020.08.042","article-title":"Challenges in cardiac and pulmonary sarcoidosis: JACC State-of-the-Art review","volume":"76","author":"Trivieri","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccm.2023.08.010_bib132","article-title":"The Examination of a TPMT gene before Administration of azathioprine in Rheumatology practice and Identification of a novel variant p.W29R","author":"Pavelcova","year":"2021","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.ccm.2023.08.010_bib133","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1007\/s10072-021-05216-z","article-title":"Cancer risk for multiple sclerosis patients treated with azathioprine and disease-modifying therapies: an Italian observational study","volume":"42","author":"La Mantia","year":"2021","journal-title":"Neurol Sci"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib134","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00042737-200102000-00017","article-title":"Inflammatory bowel disease, azathioprine and skin cancer: case report and literature review","volume":"13","author":"Austin","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.010_bib135","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1006\/clim.1999.4777","article-title":"Mechanism of action for leflunomide in rheumatoid arthritis","volume":"93","author":"Fox","year":"1999","journal-title":"Clin Immunol"},{"issue":"2\u20133","key":"10.1016\/j.ccm.2023.08.010_bib136","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0162-3109(00)00191-0","article-title":"Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases","volume":"47","author":"Herrmann","year":"2000","journal-title":"Immunopharmacology"},{"issue":"11","key":"10.1016\/j.ccm.2023.08.010_bib137","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/ard.59.11.841","article-title":"Leflunomide: mode of action in the treatment of rheumatoid arthritis","volume":"59","author":"Breedveld","year":"2000","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib138","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1183\/09031936.00195010","article-title":"Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis","volume":"38","author":"Sahoo","year":"2011","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib139","first-page":"43","article-title":"Leflunomide for chronic sarcoidosis","volume":"21","author":"Baughman","year":"2004","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib140","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.jaad.2013.10.048","article-title":"Striking leflunomide efficacy against refractory cutaneous sarcoidosis","volume":"70","author":"Bohelay","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib141","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/rheumatology\/keg156","article-title":"Successful treatment of sarcoidosis with leflunomide","volume":"42","author":"Majithia","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.ccm.2023.08.010_bib142","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.reprotox.2020.04.073","article-title":"Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide","volume":"95","author":"Henson","year":"2020","journal-title":"Reprod Toxicol"},{"issue":"Suppl 1","key":"10.1016\/j.ccm.2023.08.010_bib143","doi-asserted-by":"crossref","first-page":"s2","DOI":"10.1177\/096120330501400102","article-title":"Mechanisms of action of mycophenolate mofetil","volume":"14","author":"Allison","year":"2005","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib144","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1254\/fpj.117.131","article-title":"[Pharmacological profiles of mycophenolate mofetil (CellCept), a new immunosuppressive agent]","volume":"117","author":"Yashima","year":"2001","journal-title":"Nihon Yakurigaku Zasshi"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib145","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1159\/000345596","article-title":"Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: a retrospective study","volume":"86","author":"Brill","year":"2013","journal-title":"Respiration"},{"issue":"11","key":"10.1016\/j.ccm.2023.08.010_bib146","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.rmed.2014.09.013","article-title":"Efficacy of mycophenolate mofetil in sarcoidosis","volume":"108","author":"Hamzeh","year":"2014","journal-title":"Respir Med"},{"issue":"12","key":"10.1016\/j.ccm.2023.08.010_bib147","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.cardfail.2021.06.010","article-title":"Management of cardiac sarcoidosis using mycophenolate mofetil as\u00a0a steroid-sparing agent","volume":"27","author":"Griffin","year":"2021","journal-title":"J\u00a0Card Fail"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.010_bib148","doi-asserted-by":"crossref","first-page":"512A","DOI":"10.1016\/j.chest.2016.08.526","article-title":"Multicenter experience with mycophenolate mofetil in cardiac sarcoidosis","volume":"150","author":"Fussner","year":"2016","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.010_bib149","first-page":"693","article-title":"Coexistence of systemic sclerosis and sarcoidosis","volume":"69","author":"Godziszewska","year":"2016","journal-title":"Wiad Lek"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.010_bib150","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jccase.2015.12.008","article-title":"Combination therapy with corticosteroid and mycophenolate mofetil in a case of refractory cardiac sarcoidosis","volume":"13","author":"Kikuchi","year":"2016","journal-title":"J\u00a0Cardiol Cases"},{"key":"10.1016\/j.ccm.2023.08.010_bib151","first-page":"100782","article-title":"Non-steroidal treatment of cardiac sarcoidosis: a systematic review","volume":"34","author":"Gallegos","year":"2021","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"10","key":"10.1016\/j.ccm.2023.08.010_bib152","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.ophtha.2008.04.026","article-title":"Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation","volume":"115","author":"Galor","year":"2008","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.010_bib153","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/09273940902862992","article-title":"Mycophenolate mofetil therapy for sarcoidosis-associated uveitis","volume":"17","author":"Bhat","year":"2009","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.010_bib154","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/01.wnl.0000341278.26993.22","article-title":"Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil","volume":"72","author":"Moravan","year":"2009","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.ccm.2023.08.010_bib155","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1212\/WNL.0b013e318212aafb","article-title":"Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy","volume":"76","author":"Androdias","year":"2011","journal-title":"Neurology"},{"issue":"18","key":"10.1016\/j.ccm.2023.08.010_bib156","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1080\/14656566.2016.1258061","article-title":"Sarcoidosis: an update on current pharmacotherapy options and future directions","volume":"17","author":"Brito-Zeron","year":"2016","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"10.1016\/j.ccm.2023.08.010_bib157","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/ard.47.12.988","article-title":"Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study","volume":"47","author":"Silman","year":"1988","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.ccm.2023.08.010_bib158","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1111\/ajt.13863","article-title":"Azathioprine and risk of skin cancer in organ transplant recipients: systematic review and meta-analysis","volume":"16","author":"Jiyad","year":"2016","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.010_bib159","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jaad.2015.12.044","article-title":"High azathioprine dose and lip cancer risk in liver, heart, and lung transplant recipients: a population-based cohort study","volume":"74","author":"Na","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.ccm.2023.08.010_bib160","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1038\/ajg.2009.745","article-title":"Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study","volume":"105","author":"Armstrong","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.ccm.2023.08.010_bib161","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/aje\/kws375","article-title":"Use of azathioprine and the risk of cancer in inflammatory bowel disease","volume":"177","author":"Pasternak","year":"2013","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib162","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib163","first-page":"91","article-title":"Practical eminence and experience-based recommendations for use of TNF-alpha inhibitors in sarcoidosis","volume":"31","author":"Drent","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.ccm.2023.08.010_bib164","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","article-title":"Molecular mechanisms of action of anti-TNF-\u03b1 agents - comparison among therapeutic TNF-\u03b1 antagonists","volume":"101","author":"Mitoma","year":"2018","journal-title":"Cytokine"},{"issue":"7","key":"10.1016\/j.ccm.2023.08.010_bib165","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.010_bib166","first-page":"201","article-title":"A\u00a0double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis","volume":"23","author":"Rossman","year":"2006","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.010_bib167","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000328738","article-title":"Long-term treatment with infliximab in patients with sarcoidosis","volume":"83","author":"Hostettler","year":"2012","journal-title":"Respiration"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib168","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis","volume":"46","author":"Vorselaars","year":"2015","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib169","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0873-2159(11)70020-4","article-title":"Infliximab for treating sarcoidosis patients, Portuguese experience","volume":"17","author":"Aguiar","year":"2011","journal-title":"Rev Port Pneumol"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.010_bib170","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1378\/chest.09-2576","article-title":"The CD4+ lymphopenic sarcoidosis phenotype is highly responsive to anti-tumor necrosis factor-{alpha} therapy","volume":"137","author":"Crouser","year":"2010","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.ccm.2023.08.010_bib171","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.rmr.2010.06.011","article-title":"[Infliximab treatment for chronic sarcoidosis--a case series]","volume":"27","author":"Jounieaux","year":"2010","journal-title":"Rev Mal Respir"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib172","first-page":"123","article-title":"18F-FDG PET as a predictor of pulmonary function in sarcoidosis","volume":"28","author":"Keijsers","year":"2011","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.010_bib173","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/ard.2002.004226","article-title":"Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients","volume":"63","author":"Pritchard","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ccm.2023.08.010_bib174","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.rmed.2006.02.017","article-title":"Effectiveness of infliximab in treating selected patients with sarcoidosis","volume":"100","author":"Saleh","year":"2006","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib175","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1183\/09031936.00055213","article-title":"Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis","volume":"43","author":"Vorselaars","year":"2014","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib176","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.semarthrit.2012.10.008","article-title":"Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy","volume":"43","author":"Russell","year":"2013","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib177","first-page":"49","article-title":"C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis","volume":"27","author":"Sweiss","year":"2010","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib178","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1378\/chest.08-1876","article-title":"Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation","volume":"136","author":"Baughman","year":"2009","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.010_bib179","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1183\/09031936.00051907","article-title":"Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial","volume":"31","author":"Judson","year":"2008","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.010_bib180","first-page":"289","article-title":"Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial","volume":"32","author":"Baughman","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.010_bib181","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.semarthrit.2015.05.010","article-title":"Anti-TNF-\u03b1 therapy in refractory uveitis associated with sarcoidosis: multicenter study of 17 patients","volume":"45","author":"Riancho-Zarrabeitia","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib182","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5414\/CPP43007","article-title":"Infliximab in chronic ocular inflammation","volume":"43","author":"Baughman","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib183","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.semarthrit.2017.03.005","article-title":"Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicenter study of 132 patients","volume":"47","author":"Jamilloux","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.010_bib184","first-page":"509","article-title":"Long-term outcome of infliximab in severe chronic and refractory systemic sarcoidosis: a report of 16 cases","volume":"33","author":"Chapelon-Abric","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.ccm.2023.08.010_bib185","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.amjcard.2019.07.067","article-title":"Infliximab for refractory cardiac sarcoidosis","volume":"124","author":"Harper","year":"2019","journal-title":"Am J Cardiol"},{"issue":"10","key":"10.1016\/j.ccm.2023.08.010_bib186","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jaccas.2020.06.041","article-title":"Infliximab treatment of refractory cardiac sarcoidosis","volume":"2","author":"Asawaeer","year":"2020","journal-title":"JACC Case Rep"},{"key":"10.1016\/j.ccm.2023.08.010_bib187","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2021.02.022","article-title":"Effectiveness and safety of infliximab in cardiac Sarcoidosis","volume":"330","author":"Bakker","year":"2021","journal-title":"Int J Cardiol"},{"issue":"8","key":"10.1016\/j.ccm.2023.08.010_bib188","first-page":"1686","article-title":"Successful treatment of cardiac sarcoidosis with infliximab","volume":"35","author":"Barnabe","year":"2008","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.010_bib189","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1055\/s-2002-36522","article-title":"Therapy for extrapulmonary sarcoidosis","volume":"23","author":"Baughman","year":"2002","journal-title":"Semin Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib190","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cardfail.2020.08.013","article-title":"Clinical and imaging response to tumor necrosis factor alpha inhibitors in treatment of cardiac sarcoidosis: a multicenter experience","volume":"27","author":"Gilotra","year":"2021","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.ccm.2023.08.010_bib191","doi-asserted-by":"crossref","first-page":"676407","DOI":"10.3389\/fcvm.2021.676407","article-title":"Case report: TNFalpha antagonists are an effective therapy in cardiac sarcoidosis","volume":"8","author":"Stievenart","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"10.1016\/j.ccm.2023.08.010_bib192","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s10067-007-0614-1","article-title":"Cardiac sarcoidosis responding to monotherapy with infliximab","volume":"26","author":"Uthman","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib193","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.rmed.2008.08.016","article-title":"Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis","volume":"103","author":"Sodhi","year":"2009","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.010_bib194","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1440-1843.2009.01518.x","article-title":"Clinical outcomes in sarcoidosis after cessation of infliximab treatment","volume":"14","author":"Panselinas","year":"2009","journal-title":"Respirology"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.010_bib195","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/jnnp.2008.149989","article-title":"Treatment of refractory neurosarcoidosis with Infliximab","volume":"81","author":"Santos","year":"2010","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib196","first-page":"275","article-title":"Anti-TNF-\u03b1 therapy in the management of severe neurosarcoidosis: a report of five cases from a single centre and literature review","volume":"32","author":"Riancho-Zarrabeitia","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib197","first-page":"70","article-title":"Infliximab for refractory sarcoidosis","volume":"18","author":"Baughman","year":"2001","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"7","key":"10.1016\/j.ccm.2023.08.010_bib198","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamadermatol.2017.1162","article-title":"Efficacy and tolerance of anti-tumor necrosis factor alpha agents in cutaneous sarcoidosis: a French study of 46 cases","volume":"153","author":"Heidelberger","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib199","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/art.21468","article-title":"Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis","volume":"53","author":"Sweiss","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"20","key":"10.1016\/j.ccm.2023.08.010_bib200","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1212\/WNL.0000000000004644","article-title":"Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series","volume":"89","author":"Gelfand","year":"2017","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib201","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000847","article-title":"Infliximab treatment in pathology-confirmed neurosarcoidosis","volume":"7","author":"Fritz","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib202","first-page":"891","article-title":"Long-term outcomes of refractory neurosarcoidosis treated with infliximab","volume":"264","author":"Cohen Aubart","year":"2017","journal-title":"J\u00a0Neurol"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib203","first-page":"e2022015","article-title":"Controversies in the treatment of cardiac sarcodosis","volume":"39","author":"Obi","year":"2022","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"13","key":"10.1016\/j.ccm.2023.08.010_bib204","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.ccm.2023.08.010_bib205","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib206","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.semarthrit.2011.12.006","article-title":"Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review","volume":"42","author":"Maneiro","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib207","first-page":"834","article-title":"Use of third-line therapies in advanced sarcoidosis","volume":"38","author":"Lower","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.010_bib208","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","article-title":"Immunogenicity of biologics in chronic inflammatory diseases: a systematic review","volume":"31","author":"Strand","year":"2017","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib209","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.rmed.2013.11.019","article-title":"The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial","volume":"108","author":"Judson","year":"2014","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib210","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jaad.2012.10.056","article-title":"A\u00a0double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis","volume":"68","author":"Pariser","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.ccm.2023.08.010_bib211","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.rmed.2016.04.011","article-title":"Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab","volume":"115","author":"Crommelin","year":"2016","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib212","first-page":"46","article-title":"Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis","volume":"31","author":"Sweiss","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.010_bib213","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1183\/09031936.00169413","article-title":"Association of the TNF-\u03b1 G-308A polymorphism with TNF-inhibitor response in sarcoidosis","volume":"43","author":"Wijnen","year":"2014","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.010_bib214","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1752-699X.2011.00276.x","article-title":"Effect of the TNF-\u03b1 inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET","volume":"6","author":"Milman","year":"2012","journal-title":"Clin Respir J"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.010_bib215","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1183\/09031936.00169413","article-title":"Association of the TNF-alpha G-308A polymorphism with TNF-inhibitor response in sarcoidosis","volume":"43","author":"Wijnen","year":"2014","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib216","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00417-011-1844-0","article-title":"Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis","volume":"250","author":"Erckens","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"18","key":"10.1016\/j.ccm.2023.08.010_bib217","doi-asserted-by":"crossref","first-page":"e010952","DOI":"10.1161\/JAHA.118.010952","article-title":"Long-term corticosteroid-sparing immunosuppression for cardiac sarcoidosis","volume":"8","author":"Rosenthal","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib218","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/RLU.0000000000001124","article-title":"FDG PET\/CT evidence of effective treatment of cardiac sarcoidosis with adalimumab","volume":"41","author":"Miller","year":"2016","journal-title":"Clin Nucl Med"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib219","first-page":"76","article-title":"Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them","volume":"25","author":"Baughman","year":"2008","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.010_bib220","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/art.39667","article-title":"Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French uveitis Network","volume":"68","author":"Vallet","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib221","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10067-018-4228-6","article-title":"Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients","volume":"38","author":"Fabiani","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ccm.2023.08.010_bib222","first-page":"S47","article-title":"Tumor necrosis factor inhibition in treating sarcoidosis: the American experience","volume":"13","author":"Baughman","year":"2007","journal-title":"Revista Portuguesa de Pneumonologia"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib223","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1378\/chest.124.1.177","article-title":"Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis","volume":"124","author":"Utz","year":"2003","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib224","doi-asserted-by":"crossref","DOI":"10.1016\/S0012-3692(15)50471-6","article-title":"Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial","volume":"128","author":"Baughman","year":"2005","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib225","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1183\/09031936.00000914","article-title":"Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis","volume":"44","author":"Judson","year":"2014","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib226","first-page":"1073","article-title":"Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment","volume":"266","author":"Riller","year":"2019","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.ccm.2023.08.010_bib227","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.rmed.2018.02.009","article-title":"Efficacy and safety of infliximab biosimilar Inflectra","volume":"138S","author":"Schimmelpennink","year":"2018","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib228","doi-asserted-by":"crossref","DOI":"10.3390\/cells10020441","article-title":"Switching to an infliximab biosimilar was safe and effective in Dutch sarcoidosis patients","volume":"10","author":"Peters","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ccm.2023.08.010_bib229","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3389\/fmed.2020.00418","article-title":"Are patients at risk for recurrent disease activity after switching from Remicade((R)) to Remsima((R))? An observational study","volume":"7","author":"Xue","year":"2020","journal-title":"Front Med"},{"issue":"8","key":"10.1016\/j.ccm.2023.08.010_bib230","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00003495-200363080-00005","article-title":"Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia","volume":"63","author":"Plosker","year":"2003","journal-title":"Drugs"},{"issue":"Suppl 2","key":"10.1016\/j.ccm.2023.08.010_bib231","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","article-title":"Mechanism of action of rituximab","volume":"13","author":"Cerny","year":"2002","journal-title":"Anti Cancer Drugs"},{"issue":"8","key":"10.1016\/j.ccm.2023.08.010_bib232","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1128\/CVI.05118-11","article-title":"Disturbed homeostasis and multiple signaling defects in the peripheral blood B-cell compartment of patients with severe chronic sarcoidosis","volume":"18","author":"Lee","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"8","key":"10.1016\/j.ccm.2023.08.010_bib233","doi-asserted-by":"crossref","first-page":"e43588","DOI":"10.1371\/journal.pone.0043588","article-title":"Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels","volume":"7","author":"Saussine","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib234","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/rheumatology\/kev309","article-title":"Successful use of rituximab in refractory cardiac sarcoidosis","volume":"55","author":"Krause","year":"2016","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.010_bib235","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1212\/WNL.0b013e3181ec7ff9","article-title":"A\u00a0case of neurosarcoidosis successfully treated with rituximab","volume":"75","author":"Bomprezzi","year":"2010","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.010_bib236","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jbspin.2008.01.025","article-title":"Rituximab as a treatment alternative in sarcoidosis","volume":"75","author":"Belkhou","year":"2008","journal-title":"Joint Bone Spine"},{"issue":"10","key":"10.1016\/j.ccm.2023.08.010_bib237","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","article-title":"Longterm safety of rituximab: Final report of the rheumatoid arthritis global clinical trial program over 11 Years","volume":"42","author":"van Vollenhoven","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.010_bib238","doi-asserted-by":"crossref","first-page":"776","DOI":"10.7326\/0003-4819-37-4-776","article-title":"Effect of Acthar-c (ACTH) in sarcoidosis","volume":"37","author":"MILLER","year":"1952","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccm.2023.08.010_bib239","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.rmed.2015.11.007","article-title":"A\u00a0retrospective pilot study examining the use of Acthar gel in sarcoidosis patients","volume":"110","author":"Baughman","year":"2016","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.010_bib240","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.smim.2015.02.003","article-title":"The forgotten therapy","volume":"27","author":"Montero-Melendez","year":"2015","journal-title":"Semin Immunol"},{"key":"10.1016\/j.ccm.2023.08.010_bib241","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fneur.2013.00021","article-title":"Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone","volume":"4","author":"Ross","year":"2013","journal-title":"Front Neurol"},{"key":"10.1016\/j.ccm.2023.08.010_bib242","first-page":"1","article-title":"Outcomes of repository corticotropin gel for ocular sarcoidosis","author":"Oh","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib243","doi-asserted-by":"crossref","first-page":"90","DOI":"10.36469\/jheor.2022.33295","article-title":"Understanding predictors of response to repository corticotropin injection treatment among patients with advanced symptomatic sarcoidosis","volume":"9","author":"Bindra","year":"2022","journal-title":"J\u00a0Health Econ Outcomes Res"},{"issue":"155","key":"10.1016\/j.ccm.2023.08.010_bib244","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0147-2019","article-title":"Management of repository corticotrophin injection therapy for pulmonary sarcoidosis: a Delphi study","volume":"29","author":"Rahaghi","year":"2020","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.ccm.2023.08.010_bib245","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/TCRM.S192922","article-title":"Refractory sarcoidosis: a review","volume":"16","author":"El Jammal","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.ccm.2023.08.010_bib246","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13075-015-0880-2","article-title":"Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials","volume":"17","author":"Strand","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.ccm.2023.08.010_bib247","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A\u00a0systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.ccm.2023.08.010_bib248","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/art.40187","article-title":"The safety and Immunogenicity of live zoster Vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.ccm.2023.08.010_bib249","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","article-title":"Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity","volume":"26","author":"Schafer","year":"2014","journal-title":"Cell Signal"},{"issue":"7","key":"10.1016\/j.ccm.2023.08.010_bib250","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40265-014-0218-4","article-title":"Apremilast: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.010_bib251","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1476-5381.2009.00559.x","article-title":"Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in\u00a0vitro and in a model of psoriasis","volume":"159","author":"Schafer","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib252","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1759720X10381432","article-title":"Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases","volume":"2","author":"Schett","year":"2010","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.010_bib253","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1001\/archdermatol.2011.301","article-title":"Efficacy and safety of apremilast in chronic cutaneous sarcoidosis","volume":"148","author":"Baughman","year":"2012","journal-title":"Arch Dermatol"},{"issue":"1S","key":"10.1016\/j.ccm.2023.08.010_bib254","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.jaip.2021.10.032","article-title":"2020 NAEPP guidelines update and GINA 2021-asthma care differences, Overlap, and Challenges","volume":"10","author":"Chipps","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.ccm.2023.08.010_bib255","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/bmb\/ldq007","article-title":"New understanding and approaches to treatment in rheumatoid arthritis","volume":"94","author":"Tayar","year":"2010","journal-title":"Br Med Bull"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.010_bib256","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MCP.0000000000000906","article-title":"Hit-hard and early versus step-up treatment in severe sarcoidosis","volume":"28","author":"Vorselaars","year":"2022","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.ccm.2023.08.010_bib257","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ahj.2019.10.003","article-title":"Cardiac Sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT)","volume":"220","author":"Birnie","year":"2020","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.010_bib258","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1378\/chest.125.3.997","article-title":"Health-related quality of life of persons with sarcoidosis","volume":"125","author":"Cox","year":"2004","journal-title":"Chest"},{"issue":"155","key":"10.1016\/j.ccm.2023.08.010_bib259","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0057-2019","article-title":"The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis: a systematic review","volume":"29","author":"Vis","year":"2020","journal-title":"Eur Respir Rev"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib260","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12890-020-01290-9","article-title":"Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study","volume":"20","author":"Kahlmann","year":"2020","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.ccm.2023.08.010_bib261","unstructured":"ClinicalTrials.Gov. Effectiveness of Methotrexate Versus Prednisolone as First-line Therapy for Pulmonary Sarcoidosis (PREDMETH). U.S. National Library of Medicine. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04314193. Accessed March 5, 2023."},{"issue":"3","key":"10.1016\/j.ccm.2023.08.010_bib262","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1378\/chest.111.3.623","article-title":"Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy","volume":"111","author":"Gottlieb","year":"1997","journal-title":"Chest"},{"issue":"4 Pt 1","key":"10.1016\/j.ccm.2023.08.010_bib263","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1164\/ajrccm.149.4.8143052","article-title":"Outcome of the treatment for sarcoidosis","volume":"149","author":"Hunninghake","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.010_bib264","first-page":"52","article-title":"The late follow-up of chronic sarcoid patients previously treated with corticosteroids","volume":"15","author":"Rizzato","year":"1998","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"8","key":"10.1016\/j.ccm.2023.08.010_bib265","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/thx.54.8.742","article-title":"A\u00a0clinical approach to the use of methotrexate for sarcoidosis","volume":"54","author":"Baughman","year":"1999","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.010_bib266","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.amjcard.2015.12.033","article-title":"Effect of discontinuation of prednisolone therapy on risk of cardiac mortality associated with worsening left ventricular dysfunction in cardiac sarcoidosis","volume":"117","author":"Nagai","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccm.2023.08.010_bib267","article-title":"Efzofitimod for the treatment of pulmonary sarcoidosis","author":"Culver","year":"2022","journal-title":"Chest"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523123000795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523123000795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:17:49Z","timestamp":1759454269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523123000795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":267,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0272523123000795"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2023.08.010","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-inflammatory Therapy for Sarcoidosis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2023.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}